H5N1 vaccine (Arepanrix, GSK) — Competitive Intelligence Brief

H5N1 vaccine (Arepanrix, GSK) (H5N1 vaccine (Arepanrix, GSK)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: inactivated influenza vaccine. Area: Immunology.

phase 3 inactivated influenza vaccine Immunology Biologic

Target snapshot

H5N1 vaccine (Arepanrix, GSK) (H5N1 vaccine (Arepanrix, GSK)) — University Health Network, Toronto. Arepanrix is an inactivated H5N1 influenza vaccine that stimulates the immune system to produce antibodies and cellular immunity against the H5N1 avian influenza virus.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
H5N1 vaccine (Arepanrix, GSK) TARGET	H5N1 vaccine (Arepanrix, GSK)	University Health Network, Toronto	phase 3	inactivated influenza vaccine
Trivalent Influenza Vaccine	Trivalent Influenza Vaccine	MedImmune LLC	marketed	Inactivated influenza vaccine
High-Dose Quadrivalent Influenza Vaccine	High-Dose Quadrivalent Influenza Vaccine	Tor Biering-Sørensen	marketed	Inactivated influenza vaccine
Anti-H1N1v Vaccine	Anti-H1N1v Vaccine	Institut National de la Santé Et de la Recherche Médicale, France	marketed	Inactivated influenza vaccine	H1N1 influenza virus hemagglutinin and neuraminidase antigens
Trivalent sub-unit influenza vaccine	Trivalent sub-unit influenza vaccine	University of Witwatersrand, South Africa	marketed	inactivated influenza vaccine
adjuvanted Arepanrix	adjuvanted Arepanrix	University of British Columbia	marketed	Adjuvanted inactivated influenza vaccine	H1N1 influenza virus hemagglutinin and neuraminidase antigens
Influsplit SSW® 2005/2006	Influsplit SSW® 2005/2006	GlaxoSmithKline	marketed	Inactivated influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (inactivated influenza vaccine class)

1. Seqirus · 3 drugs in this class
2. Center for Disease Prevention and Control of Beijing Military Region · 2 drugs in this class
3. Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
4. Sinovac Biotech Co., Ltd · 2 drugs in this class
5. La Jolla Institute for Immunology · 1 drug in this class
6. Mount Sinai Hospital, Canada · 1 drug in this class
7. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
8. University of Sao Paulo · 1 drug in this class
9. GlaxoSmithKline · 1 drug in this class
10. University of Witwatersrand, South Africa · 1 drug in this class